Zhitai Bio
质肽生物
Zhitai Bio (Beijing Zhitai Biopharmaceutical) is a recombinant protein drug innovation platform focused on metabolic diseases, founded by Xujia Zhang, who serves as chairman and CEO . BlueRun Ventures backed it early — leading its 100-million-yuan-plus Series B and doubling down in a nearly RMB 200 million Series B+ in late 2023 — and counts it among the more pioneering peptide-drug companies in its portfolio, alongside Nankai Hecheng and ZhuanYan Bio . Most recently, in early March 2026, it closed a Series C of over RMB 500 million, with Qiming Venture Partners participating . Proceeds from the B round were earmarked mainly for clinical development of its pipeline .
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners and Nearly 40 Portfolio Companies Named to VBData 2026 Future Healthcare 100
China's most authoritative and influential innovation benchmark for the healthcare industry
After Breaking Ground, Growth Follows | Quarterly
The stage is set. Your entrance awaits.
Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including Top 4 on ChinaVenture's 2025 China Best VC Firms List
The "ChinaVenture Ranking" has been published for 20 consecutive years, and is known throughout the industry for its professionalism, authority, and rigor. It is regarded as a bellwether for China's equity investment industry and serves as an important reference for capital commitments from many large institutional LPs.
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.07, 2026.3.4
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
5Y News | QLT Biotherapeutics Raises Over 500 Million RMB in Series C Funding
Zhitai Biotech Closes Over 500 Million Yuan Series C Round to Accelerate Core Clinical Pipeline Development
BlueRun Ventures Continues to Double Down as QLT Biotherapeutics Closes Over RMB 500 Million Series C Round | BlueRun Family
Accelerate core clinical pipeline development
BlueRun Ventures in Conversation with QUA Biotech, AllinkBio, and Zenitar: Breaking Out of the Red Sea — The "Value" Evolution of China's Innovative Drugs
The Leap from "Imitation and Followership" to "Original Innovation"
Dawn Breaks, Toward the Light | BlueRun Ventures 2025 Annual Fund Partners Meeting
Welcoming the Dawn of Technology
Planting Spring in the Wind | Quarterly
On the Move
The Power of Waiting to Grow in the Snow | BlueRun Ventures Bi-Monthly Report
"Clear skies after a flurry of snow"
Beyond the Quadrant: Forging an Undefined Path | BlueRun Ventures 2024 Annual Fund Partners Meeting
Breaking Through a Mental Block
A New Drug King Is About to Be Crowned. Does Peptide Still Have Its Next Billion-Dollar Target? | BlueRun Ventures Viewpoint
You can only find things when you're not looking for them.
Breaking Through Your Mental Block in an Olympic Year | BlueRun Ventures Bi-Monthly Report
OUVRONS GRAND LES JEUX This text is already in French, not Chinese. It translates to English as: **LET THE GAMES BEGIN** Or more literally: "Let's open the games wide" / "Let the games open grandly" (This is the official slogan/tagline for the Paris 2024 Olympic and Paralympic Games.)
Zhitai Bio's GLP-1 Product Semaglutide Injection Licensed to Tonghua Dongbao | BlueRun Ventures Headlines
It has the potential to become one of the first semaglutide biosimilars to be approved and commercially launched in China.
The Trillion-Yuan Blueprint for Peptide Drugs: From Diabetes Medication to Weight-Loss Wonder | BlueRun Ventures Biotech Forum Recap
From Pharmaceuticals to Consumer Goods: A Wave of Value Creation
The Future Looks Very Different | December & January Bimonthly Report
Witnessing BlueRun Ventures' "Defining Moment"
BlueRun Ventures Quarterly Investment & Financing Overview | 2023 Q4
Sector distribution spans artificial intelligence, enterprise services, hard tech, and biotech, among others.
BlueRun Ventures and Its Portfolio Companies Win Multiple Awards from Forbes China, TMTpost, Jiemian News, and Cyzone
Standing alongside founders from zero to one to redefine the future.
Looking at the Other Side of the Coin | October & November Report
Grateful for what life has given
BlueRun Ventures | BlueRun Ventures Continues to Double Down, Zhitai Bio Closes Nearly RMB 200 Million Series B+ Round
Focused on developing recombinant protein therapeutics using an *E. coli*-based technology platform.
A Pill's Journey from Lab to Industry | BlueRun Ventures Biotech Salon Series
The investment logic in biotech has quietly shifted.
